Bahar Arıcan Tarım
Research Subjects
Bahar Arıcan Tarım has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Tugce Uskur
Department of Medical Pharmacology, Faculty of Medicine, Kırklareli University, Kırklareli, Türkiye
3 shared publications - Gokhan Faikoglu
Department of Pharmacology, Cerrahpasa Faculty of Medicine, Istanbul University, Cerrahpasa, Istanbul, Turkey
2 shared publications - Elif Ari
Department of Nephrology, Bahcesehir University, Istanbul, Turkey
1 shared publication - Emre Çamur
Department of Urology, University of Health Sciences, Kartal Dr. Lutfi Kırdar City Hospital, Istanbul
1 shared publication - Fayegh Yousefi
Neurosciences Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
1 shared publication - Fehmi Narter
Mehmet Ali Aydinlar Univ, Kadikoy Hosp, Dept Urol, Istanbul, Turkiye
1 shared publication
Latest Publications
- Open Access
- 24 October 2025
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 6 (5) , 443-446
Comparison of chemotherapy informed consent forms written by humans and artificial intelligence: exploring the potential of AI-assisted health communication
Aims: Informed consent is a legal requirement prior to chemotherapy treatment, and its readability is critical to ensuring that patients are adequately informed before undergoing a therapy associated with significant side effects and complications. This study aimed to compare the readability levels of informed consent documents for chemotherapy, authored by a human and generated by artificial intelligence (AI), in both their original Turkish versions and English translations. Methods: This in silico study evaluated two chemotherapy informed consent forms: one written by a healthcare professional currently used at Kartal Dr. Lütfi Kırdar City Hospital, and the other generated using the GPT-4 language model. Both forms were assessed in their original Turkish versions and in their English translations. Readability of the Turkish texts was measured using the Ateşman index, while the English versions were evaluated using the Flesch-Kincaid grade level (FKGL) formula. Results: The human-written Turkish form had an Ateşman score of 62.2, corresponding to the 9th–10th grade reading level, while the AI-generated Turkish form had a slightly higher score of 65.7, also indicating a 9th–10th grade readability level. In the English versions, the human-authored form scored 16.56 on the FKGL scale, representing a "college graduate" reading level and classified as “extremely difficult”. In contrast, the AI-generated form scored 14.07, corresponding to a “college junior” level and classified as “professional” in terms of reading difficulty. Conclusion: Although both forms require advanced reading skills, the AI-generated documents were found to be shorter, more concise, and had higher readability scores. These findings suggest that AI may serve as a supportive tool in simplifying medical texts and enhancing patient communication-particularly in information-dense fields such as pharmacology.
- 24 October 2025
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 6 (5) , 443-446
Open AccessComparison of chemotherapy informed consent forms written by humans and artificial intelligence: exploring the potential of AI-assisted health communication
Aims: Informed consent is a legal requirement prior to chemotherapy treatment, and its readability is critical to ensuring that patients are adequately informed before undergoing a therapy associated with significant side effects and complications. This study aimed to compare the readability levels of informed consent documents for chemotherapy, authored by a human and generated by artificial intelligence (AI), in both their original Turkish versions and English translations. Methods: This in silico study evaluated two chemotherapy informed consent forms: one written by a healthcare professional currently used at Kartal Dr. Lütfi Kırdar City Hospital, and the other generated using the GPT-4 language model. Both forms were assessed in their original Turkish versions and in their English translations. Readability of the Turkish texts was measured using the Ateşman index, while the English versions were evaluated using the Flesch-Kincaid grade level (FKGL) formula. Results: The human-written Turkish form had an Ateşman score of 62.2, corresponding to the 9th–10th grade reading level, while the AI-generated Turkish form had a slightly higher score of 65.7, also indicating a 9th–10th grade readability level. In the English versions, the human-authored form scored 16.56 on the FKGL scale, representing a "college graduate" reading level and classified as “extremely difficult”. In contrast, the AI-generated form scored 14.07, corresponding to a “college junior” level and classified as “professional” in terms of reading difficulty. Conclusion: Although both forms require advanced reading skills, the AI-generated documents were found to be shorter, more concise, and had higher readability scores. These findings suggest that AI may serve as a supportive tool in simplifying medical texts and enhancing patient communication-particularly in information-dense fields such as pharmacology.
- Open Access
- 15 September 2025
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 7 (5) , 647-651
The effect of vitamin D replacement therapy on insulin resistance: a retrospective study
Aims: This study retrospectively evaluated the effect of a 3-month vitamin D replacement therapy in patients diagnosed with insulin resistance (IR) and low vitamin D levels. The relationship between changes in vitamin D levels and IR was investigated. Methods: A total of 98 patients with low serum vitamin D levels and HOMA-IR >2.5, who were admitted to the internal medicine outpatient clinic between January 1 and December 31, 2023, were included in this retrospective study. Sociodemographic characteristics and pre-and post-treatment biochemical parameters were obtained from medical records. Post-supplementation levels of vitamin D, glucose, insulin, and HOMA-IR were analyzed. Pre-and post-treatment values were compared using paired t-tests. The relationship between changes in vitamin D levels and HOMA-IR scores was assessed using Spearman correlation analysis. Results: Of the 98 patients, 85.7% were female and 14.3% were male, with a mean age of 39.09±11.45 years. A significant reduction in HOMA-IR score was observed after vitamin D supplementation (pre: 4.54±2.05; post: 3.01±1.28; p
- 15 September 2025
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 7 (5) , 647-651
Open AccessThe effect of vitamin D replacement therapy on insulin resistance: a retrospective study
Aims: This study retrospectively evaluated the effect of a 3-month vitamin D replacement therapy in patients diagnosed with insulin resistance (IR) and low vitamin D levels. The relationship between changes in vitamin D levels and IR was investigated. Methods: A total of 98 patients with low serum vitamin D levels and HOMA-IR >2.5, who were admitted to the internal medicine outpatient clinic between January 1 and December 31, 2023, were included in this retrospective study. Sociodemographic characteristics and pre-and post-treatment biochemical parameters were obtained from medical records. Post-supplementation levels of vitamin D, glucose, insulin, and HOMA-IR were analyzed. Pre-and post-treatment values were compared using paired t-tests. The relationship between changes in vitamin D levels and HOMA-IR scores was assessed using Spearman correlation analysis. Results: Of the 98 patients, 85.7% were female and 14.3% were male, with a mean age of 39.09±11.45 years. A significant reduction in HOMA-IR score was observed after vitamin D supplementation (pre: 4.54±2.05; post: 3.01±1.28; p
- Open Access
- 3 January 2024
- Published by The European Research Journal in The European Research Journal
- Vol. 10 (1) , 105-117
Effects of insulin resistance on cardiovascular risk factors in obese and non-obese patients
Objectives: It is known that insulin resistance increases cardiovardiovascular risk. But it could not obviously be understood whether insulin resistance itself or the metabolic syndrome parameters, like obesity, that already exist in most of them, are responsible for this increased risk. Our aim is to determine cardiovascular risks in obese and non-obese insulin-resistant patients. Methods: One hundred thirty-nine patients were included in the study. They were divided into 4 groups: Group 1 (having obesity and insulin resistance), Group 2 (having only insulin resistance but not obesity), Group 3 (having obesity but not insulin resistance), and Group 4 (having neither obesity nor insulin resistance). Patients having any systemic disease were excluded. Insulin resistance is calculated via Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) formula. Electrocardiographic, echocardiographic and lipid parameters of these patients were compared. Results: High-density lipoprotein (HDL) levels of Group-4 were higher than Group 1 and Group 2. There was no statistical difference in HDL cholesterol levels between Group 3 and the others. Triglyceride and very low-density lipoprotein levels were higher in Group 1. There was no difference in P wave dispersion between the groups. In echocardigraphy, epicardial fat tissue thickness of Group 1 was significantly higher. Prevalance of diastolic dysfunction was higher in Group 1 compared to Group 4. Conclusions: Insulin resistance itself is a risk factor for low HDL levels independent of obesity. When obesity is added to insulin resistance, other cardiovascular risk factors appear, like high triglyceride levels, increase in epicardial fat tissue thickness and presence of diastolic dysfunction. Early detection of insulin resistance may alert us to the risks of cardiovascular diseases.
- 3 January 2024
- Published by The European Research Journal in The European Research Journal
- Vol. 10 (1) , 105-117
Open AccessEffects of insulin resistance on cardiovascular risk factors in obese and non-obese patients
Objectives: It is known that insulin resistance increases cardiovardiovascular risk. But it could not obviously be understood whether insulin resistance itself or the metabolic syndrome parameters, like obesity, that already exist in most of them, are responsible for this increased risk. Our aim is to determine cardiovascular risks in obese and non-obese insulin-resistant patients. Methods: One hundred thirty-nine patients were included in the study. They were divided into 4 groups: Group 1 (having obesity and insulin resistance), Group 2 (having only insulin resistance but not obesity), Group 3 (having obesity but not insulin resistance), and Group 4 (having neither obesity nor insulin resistance). Patients having any systemic disease were excluded. Insulin resistance is calculated via Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) formula. Electrocardiographic, echocardiographic and lipid parameters of these patients were compared. Results: High-density lipoprotein (HDL) levels of Group-4 were higher than Group 1 and Group 2. There was no statistical difference in HDL cholesterol levels between Group 3 and the others. Triglyceride and very low-density lipoprotein levels were higher in Group 1. There was no difference in P wave dispersion between the groups. In echocardigraphy, epicardial fat tissue thickness of Group 1 was significantly higher. Prevalance of diastolic dysfunction was higher in Group 1 compared to Group 4. Conclusions: Insulin resistance itself is a risk factor for low HDL levels independent of obesity. When obesity is added to insulin resistance, other cardiovascular risk factors appear, like high triglyceride levels, increase in epicardial fat tissue thickness and presence of diastolic dysfunction. Early detection of insulin resistance may alert us to the risks of cardiovascular diseases.
- 1 September 2023
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 10 (3) , 194-198
Metabolic Syndrome and Benign Prostatic Hyperplasia/What Component of Metabolic Syndrome Is Related to Benign Prostatic Hyperplasia?
- 1 September 2023
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 10 (3) , 194-198
Metabolic Syndrome and Benign Prostatic Hyperplasia/What Component of Metabolic Syndrome Is Related to Benign Prostatic Hyperplasia?
- Open Access
- 1 January 2023
- Published by XMLink in Yonsei Medical Journal
- Vol. 64 (3) , 175-180
Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study
Tarim BA, et al. Yonsei Med J. 2023 Mar;64(3):175-180. https://doi.org/10.3349/ymj.2022.0287
- 1 January 2023
- Published by XMLink in Yonsei Medical Journal
- Vol. 64 (3) , 175-180
Open AccessDo Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study
Tarim BA, et al. Yonsei Med J. 2023 Mar;64(3):175-180. https://doi.org/10.3349/ymj.2022.0287
- Open Access
- 15 September 2019
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 62 (9) , 360-366
Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children
Attention deficit-hyperactivity disorder (ADHD) is one of the most common chronic behavioral disorders in school-aged children. This study aimed to evaluate the effect of omega-3 supplementation as an alternative therapy for ADHD, which can be caused by vitamin and mineral deficiencies. This was a double-blinded clinical trial study. Sixty-six children with ADHD (aged 6-12 years) referred to our child and adolescent psychiatric educational and therapeutic clinic were selected based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria. Instruments including the Parent ADHD Rating Scale were used to assess ADHD at 0, 2, 4, and 8 weeks during the study. The results showed no statistically significant difference between the methylphenidate with omega-3 group and methylphenidate with placebo group based on the Parents ADHD Rating Scale between week 0 (P≥0.96) and week 8 (P≥0.75). There were no significant intergroup differences between the Inattention (P≥0.48) and hyperactivity/impulsivity (P≥0.80) subscale scores on the Parents ADHD Rating Scale. The most common drug complications in the methylphenidate with placebo and methylphenidate with omega-3 groups were anorexia (27 [54%] vs. 41 [60.29%], respectively) and diarrhea (10 [20%] vs. 8 [11.76%], respectively), but the differences were not statistically significant (P> 0.05). Our results demonstrate that a specific dose of omega-3 for 8 weeks had no effect on ADHD.
- 15 September 2019
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 62 (9) , 360-366
Open AccessEffect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children
Attention deficit-hyperactivity disorder (ADHD) is one of the most common chronic behavioral disorders in school-aged children. This study aimed to evaluate the effect of omega-3 supplementation as an alternative therapy for ADHD, which can be caused by vitamin and mineral deficiencies. This was a double-blinded clinical trial study. Sixty-six children with ADHD (aged 6-12 years) referred to our child and adolescent psychiatric educational and therapeutic clinic were selected based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria. Instruments including the Parent ADHD Rating Scale were used to assess ADHD at 0, 2, 4, and 8 weeks during the study. The results showed no statistically significant difference between the methylphenidate with omega-3 group and methylphenidate with placebo group based on the Parents ADHD Rating Scale between week 0 (P≥0.96) and week 8 (P≥0.75). There were no significant intergroup differences between the Inattention (P≥0.48) and hyperactivity/impulsivity (P≥0.80) subscale scores on the Parents ADHD Rating Scale. The most common drug complications in the methylphenidate with placebo and methylphenidate with omega-3 groups were anorexia (27 [54%] vs. 41 [60.29%], respectively) and diarrhea (10 [20%] vs. 8 [11.76%], respectively), but the differences were not statistically significant (P> 0.05). Our results demonstrate that a specific dose of omega-3 for 8 weeks had no effect on ADHD.